To determine the objective overall response of re-treatment with cetuximab-based chemotherapy
in patients upon disease progression while under observation, who had previously responded to
first-line or second-line treatment with cetuximab-based chemotherapy for metastatic
colorectal cancer (mCRC), but had stopped treatment for reasons other than disease
progression.